Back

TenNor reports 100% success in Phase IIa PJI trial, starts Phase IIb

Verifying
  • TenNor Therapeutics reported Phase IIa results for intra-articular TNP-2092 in PJI patients.
  • Five of five early or acute PJI patients achieved six-month treatment success.
  • China's NMPA approved and TenNor initiated a multicenter Phase IIb trial.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.